This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Legal battle brewing over Novo Nordisk's Ozempic patent in India

By Freny Patel ( May 30, 2025, 06:45 GMT | Insight) -- A major legal battle is brewing in India's pharmaceutical sector, as generic drugmaker Dr. Reddy's Laboratories challenges Novo Nordisk's patent for semaglutide — the active ingredient in the popular diabetes and weight-loss drug Ozempic. This comes as Novo Nordisk reportedly prepares to launch Ozempic in India next year, even as its patent for semaglutide is reportedly set to expire in India in January 2026. In what is poised to become a significant legal showdown in India's pharmaceutical sector, domestic drugmaker Dr. Reddy's Laboratories has challenged the validity of Danish pharma giant Novo Nordisk's semaglutide patent — the active ingredient in the popular diabetes and weight loss medication Ozempic....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections